期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 2, 页码 1536-1551出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01280
关键词
-
资金
- NCI [1R01CA197178]
- Cancer Research UK [FC001115]
- UK Medical Research Council
- Wellcome Trust
This study identified a series of N-trisubstituted pyrimidine derivatives as potential drugs for inhibiting mutant RET kinase. Compound 20 was found to strongly inhibit both RET and RETV804M, and also exhibited anti-proliferative activity against CCDC6-RET-driven LC-2/ad cells.
Mutations of the rearranged during transfection (RET) kinase are frequently reported in cancer, which make it as an attractive therapeutic target. Herein, we discovered a series of N-trisubstituted pyrimidine derivatives as potent inhibitors for both wild-type (wt) RET and (RETM)-M-V804, which is a resistant mutant for several FDA-approved inhibitors. The X-ray structure of a representative inhibitor with RET revealed that the compound binds in a unique pose that bifurcates beneath the P-loop and confirmed the compound as a type I inhibitor. Through the structure-activity relationship (SAR) study, compound 20 was identified as a lead compound, showing potent inhibition of both RET and RETV804M. Additionally, compound 20 displayed potent antiproliferative activity of CCDC6-RET-driven LC-2/ad cells. Analysis of RET phosphorylation indicated that biological activity was mediated by RET inhibition. Collectively, N-trisubstituted pyrimidine derivatives could serve as scaffolds for the discovery and development of potent inhibitors of type I RET and its gatekeeper mutant for the treatment of RET-driven cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据